Drug intelligence / Profile preview

depatuxizumab

Development stage: Phase 2
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous Infusion

Overview

Depatuxizumab is a humanized recombinant monoclonal antibody that specifically targets activated Epidermal Growth Factor Receptor (EGFR), including both wild-type and EGFRvIII mutant forms. It was developed by AbbVie, with Ludwig Institute for Cancer Research as the originator. Depatuxizumab functions by binding to EGFR, thereby inhibiting its signaling and suppressing tumor growth. It has been investigated as a standalone agent in early-phase clinical trials for advanced solid tumors and also serves as the antibody component in the antibody-drug conjugate depatuxizumab mafodotin (ABT-414).

Other names: depatux

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on depatuxizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on depatuxizumab.

Explore the full profile